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Abstract
Dermatitis herpetiformis is an autoimmune skin disease, which is strongly related to 
coeliac disease. Moreover, some authors accept it as the skin manifestation of coeliac 
disease. It is a chronic, recurrent disease with polymorphic skin eruptions and pruritus. 
Dermatitis herpetiformis is a disease of the young adults mostly, but can be seen at any 
age. It is characterized by papules, vesicles, excoriations, and urticarial plaques clinically. 
Histopathological examination reveals subepidermal separation, and with this finding, 
it needs to be differentiated from linear IgA bullous dermatitis and bullous pemphigoid. 
In this case, direct immunofluorescence is helpful. Granular deposition of IgA is pathog-
nomonic for dermatitis herpetiformis. Dermatitis herpetiformis can accompany other 
autoimmune disorders such as type I diabetes mellitus, thyroid diseases, vitiligo, and 
collagen tissue diseases. Dermatitis herpetiformis is, usually, successfully treated with 
dapsone and gluten-free diet.
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1. Introduction
Autoimmune bullous diseases constitute one of the main groups of dermatological diseases. 
One of these bullous disorders is dermatitis herpetiformis (DH). Dermatitis herpetiformis is 
a chronic, recurring, autoimmune, inflammatory skin disease, which is characterized by pru-
ritic polymorphic lesions [1].
DH was first coined by the dermatologist, Louis Duhring, in 1884. Later, in 1888, Brocq identi-
fied a similar skin disease “polymorphic pruritic dermatitis.” That is why, the disease is also 
named as Duhring-Brocq’s disease or mostly Duhring’s disease [2].
DH and celiac disease (CD) are two entities that are strongly related. Moreover, there are 
evidences that claim that DH is the cutaneous manifestation of CD, because both diseases are 
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seen in gluten-sensitive persons and share similar HLA haplotypes such as DQ2 and DQ8 [3]. 
Today, we know that gastrointestinal symptoms in DH are generally mild or absent. We also 
know that only 24% of the CD patients have skin lesions resembling DH [4]. Based on these, 
we can consider these two diseases as different entities that are closely related.
DH is mostly reported in Caucasians although it is being increasingly reported in the Japanese 
population [5, 6]. Its incidence is reported to be 11.5–75.3/100,000 in different countries [7, 8]. The 
disease is rare in the Far East and even rarer in Afro-Americans [9]. DH mostly affects individuals 
in the third or fourth decades, but patients of any age between 2 and 90 have been reported so far. 
For example, in Italy, there are many pediatric DH patients [10]. In the adult population, males 
are more commonly affected, whereas female-to-male ratio ranges from 2:1 to 4:1 in children [11].
2. Pathogenesis
The pathogenesis of DH is a complex process in which autoimmune factors, genetics, HLA 
predisposition, and environmental factors take part [12]. In a study of monozygotic twins, the 
concordance rate of the disease was found to be 0.91, which was higher than expected [13]. In 
two other studies, 10 and 19% of the DH patients had a first-degree relative with a diagnosis 
of DH [14, 15].
One possible gene associated with CD and DH is myosin 9B (MYO9B) on chromosome 9p13 
[16, 17]. MYO9B regulates actin cytoskeleton functions, cell integrity, and gut barrier perme-
ability. Increased permeability of the gastrointestinal barrier may allow more gluten penetra-
tion, and as a result, immunological processes start in CD and DH [18].
In DH, close relationship with some HLA loci has also been reported. Close association 
between DH and HLA-DQ2/HLA-DQ8 has been emphasized. In a study of 50 patients, 86% 
had HLA-DQ2 allele and the rest HLA-DQ8 allele [19].
Tissue transglutaminase (tTG) is a cytoplasmic, calcium-dependent enzyme and is the major 
autoantigen for CD [20]. It stabilizes the cytoskeleton and the extracellular matrix by protein 
polymerization. As a result, it regulates the cell matrix adhesion, cell migration, and pro-
liferation [21, 22]. tTG is also found in the skin, dermal capillaries, and basal keratinocytes 
[23]. tTG acts on the alcohol-soluble part of gluten, which is the gliadin, and transforms it to 
an autoantigen, which has an affinity for HLA-DQ2 on antigen-presenting cells. As a result, 
T cells are stimulated and an inflammatory cascade starts [21, 24, 25]. In addition, tTG-
gliadin complexes are formed and these complexes generate a robust autoantibody response 
[21, 24, 25]. This continuous inflammation causes villous atrophy and intestinal damage.
The autoantibodies in DH and CD are mostly of IgA type. Sometimes, IgG can also be seen 
and is important in IgA deficiency [26]. The characteristic finding of DH is the deposition of 
IgA in the tips of dermal papillae and along the basal membrane in a granular manner. This 
accumulation can be seen on direct immunofluorescence of the perilesional skin [27–29]. The 
IgA deposits trigger an inflammatory reaction, which results in neutrophilic deposition and 
vesicle formation [30].
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In DH, epidermal transglutaminase (eTG) seems to be the main autoantigen rather than tTG. 
eTG colocalizes with IgA [27–30]. The role of eTG in the skin is the cross-linking and the main-
tenance of cornified envelope integrity [31, 32]. eTG is expressed in dermis, small intestine, 
brain, and testes. Individuals with DH have IgA antibodies specific for eTG and sometimes 
for tTG [29]. Blood levels of IgA-type anti-eTG antibodies are more sensitive than IgA-type 
anti-tTG antibodies, identifying DH [33, 34]. One recent study showed that only half of the 
DH patients were positive for IgA anti-eTG, claiming that other possible factors take part in 
the pathogenesis of the disease [27]. It was shown that skin deposits of IgA immune com-
plexes disappear with gluten-free diet (GFD) and reappear with rechallenge supporting the 
effect of gluten in the pathogenesis of DH [35].
Lifestyle was also shown to affect the disease activity. For example, iodine use or iodine-rich 
foods (such as shellfish) cause flare of DH [36]. Triiodomethane that is used during dental 
procedures may also cause exacerbation of the disease [37]. In two studies, it was claimed that 
tobacco had protective effects in CD patients similar to that observed in ulcerative colitis. But 
the mechanism is unclear and is not shown in DH patients [38, 39].
3. Clinical findings
DH is characterized by polymorphic lesions such as 1–3 mm papules, vesicles, small blisters, 
erosions, crusts, excoriations, and secondary infections [40]. Sometimes, urticarial plaques, 
lichenification secondary to scratching, and purpura of the fingers and toes can also be pres-
ent [41, 42]. Due to scratching, representative lesions are mostly missing and all the physician 
sees is excoriations. In DH, the lesions are mostly seen in the extensor aspects of the body such 
as the anterior thigh, elbows, knees, buttocks, shoulders, sacral region, scalp, fingers, and toes. 
Oral mucosa is mostly spared [43]. The lesions, if not secondarily infected, heal without scar 
formation but with postinflammatory hyperpigmentation. In mild disease, symptomatic and 
disease-free periods alternate, whereas in severe disease, the symptoms are continuous with 
variable severity [42]. Figure 1 demonstrates polymorphic eruption consisting of excoriated 
papules and erosions.
Palmoplantar purpura, which is an uncommon manifestation of DH, is mostly reported in pedi-
atric patients. Petechiae are seen on the soles and palms sparing the dorsal surfaces. Interestingly, 
the dominant hands are affected more commonly suggesting that trauma can be the causative 
agent [44, 45]. There are also few individuals with DH, manifesting with leukocytoclastic vascu-
litis-like appearance, urticarial wheals, palmoplantar keratosis, and prurigo pigmentosa [46–49].
Mucosal involvement is rare in individuals with DH. Most mucosal lesions lack confirmation 
with direct immunofluorescence studies. These mucosal lesions are mostly thought to appear 
due to DH-related conditions such as CD or other autoimmune connective tissue disorders [50].
Dental abnormalities have also been reported in individuals with DH and CD. Enamel defects 
in permanent teeth, horizontal grooves, defects in enamel color, and enamel pits are the most 
commonly reported dental findings [51–53].
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Only 20% of the DH patients develop gastrointestinal symptoms. These symptoms include 
diarrhea, anemia due to malabsorption, steatorrhea, weight loss, and malnutrition [54].
In children with DH, short stature and delayed puberty and development can be observed [55].
4. Dermatitis herpetiformis–associated disorders
DH is an autoimmune disorder and we know that different types of autoimmune disorders can 
coexist. Thyroid abnormalities may accompany DH. Thyroid microsomal antibodies are posi-
tive in these patients [56–58]. Thyroid involvement is mostly in the form of hypothyroidism 
rather than hyperthyroidism [56]. Individuals with DH have a higher risk of type I diabetes 
mellitus with a prevalence of 2–5% [59, 60]. Pernicious anemia, Addison’s disease, vitiligo, and 
alopecia areata are other autoimmune diseases that are reported to coexist with DH [61–63].
Autoimmune connective tissue diseases, such as rheumatoid arthritis, systemic lupus erythe-
matosus, and Sjogren’s syndrome are also commonly seen in DH patients [60, 64]. Table 1 
summarizes the autoimmune disorders that may accompany DH.
Figure 1. Excoriated papules and eroded vesicles in a patient with DH.
Autoimmune Bullous Diseases104
Gjone and Nordoy, in 1970, reported for the first time that individuals with DH had a higher 
risk of lymphoma [65]. Some other studies also reported such relationship later on [4, 66–69]. 
First-degree relatives of the patients with DH are believed not to have a higher risk of lym-
phoma, on the contrary to CD [66, 70]. There are fewer studies asserting the contrary. Lewis 
et al. in 2008 reported no increased risk of morbidity or mortality in DH patients [71].
5. Diagnosis
Early diagnosis of DH is essential to relieve the patient. In consequence to understanding the 
pathogenesis of the disease, numerous serologic tests were developed. The proper diagnosis 
of DH is made with the evaluation of physical examination, immunofluorescence studies, 
routine histopathological examination, and the serology [3].
An ideal dermatological examination starts with inspection. Suspicious lesions, mostly exco-
riations, are commonly distributed on extensor aspects of the body. An intact vesicle, if visible, 
is the most specific diagnostic lesion. The patients mostly complain of itching that exacerbates 
during night, which may also be helpful in the diagnosis.
Routine histopathological examination must be performed with a specimen that contains an 
intact vesicle if possible [72]. Diagnostic findings are subepidermal clefts and neutrophilic infil-
tration at the tip of the dermal papillae. Sometimes, a few eosinophils can also be seen. These 
abscesses formed by neutrophils and eosinophils are called Pierard microabscess [73]. A peri-
vascular mixed inflammation is usually present [65]. The histopathology of LABD, bullous pem-
phigoid, and bullous lupus erythematosus can resemble such features. Immunofluorescence 
studies help us to differentiate these similar entities [74]. In DH, granular IgA deposition at 
the tips of dermal papillae is pathognomonic. In LABD, linear deposition of IgA is observed. 
Sometimes, in less than 5% of the patients, the granular IgA deposits in DH along the basement 
membrane can be evaluated as linear by mistake [3]. In Japanese patients, IgA deposition in a 
fibrillary pattern can also be seen [75]. The immunological deposits are not affected after phar-
macological therapy. İnstead, the deposits diminish on a gluten-free diet (GFD) [76]. It must 
be kept in mind that IgA deposition is best seen in normal-appearing perilesional skin rather 
than in the lesional skin [77]. Warren et al. reported that in 35–40% of the individuals with 
• Hashimoto’s thyroiditis
• Type I diabetes mellitus
• Pernicious anemia
• Addison’s disease
• Alopecia areata
• Sarcoidosis
• Scleroderma
• Sjogren’s disease
• Vitiligo
• Systemic lupus erythematosus
• Myasthenia gravis
Table 1. Autoimmune diseases associated with dermatitis herpetiformis.
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DH, the histopathological findings are not demonstrative enough, i.e. sometimes the only find-
ing is the perivascular lymphocytic infiltrate and/or slight dermal papillary inflammation [78]. 
Sometimes, apart from IgA, deposition of granular IgM and C3 at the dermoepidermal junc-
tion can also be present [79]. In Figure 2, typical deposition of granular IgA is demonstrated.
Histopathological examination of the intestine is not a must for the diagnosis of DH. But it is 
a known fact that even in DH patients without gastrointestinal symptoms, the inflammatory 
changes are present in the small bowel [80].
Serological tests are used in conjunction with pathology and immunopathology. Circulating 
IgA-type antibodies against endomysium are detected in both DH and CD. Endomysium is 
the loose connective tissue surrounding muscle fibers. This test is based on indirect immu-
nofluorescence with monkey esophagus as the substrate [81]. IgA-type anti-tTG testing has 
high specificity and sensitivity and can be used to differentiate DH from LABD, in case of 
necessity, showing the mucosal damage [82]. Anti-eTG testing has high sensitivity and even 
higher specificity in diagnosis of DH. Both the levels of anti-tTG and anti-eTG reflect the level 
of intestinal damage. Any individual on a strict GFD shows low levels of antiendomysial, 
anti-tTG, and anti-eTG antibodies. Based on this, these antibodies can be used to evaluate the 
adherence to GFD [65]. In CD, selective IgA deficiency is seldom seen, which causes a possible 
delay in the diagnosis of the disease. But this is not the case for DH, i.e. IgA deficiency is not 
common in DH [83]. Antibodies such as antigliadin, antireticulina, antineoepitope tTG, and 
anti-GAF3X are also found in DH [84–86].
In individuals with DH, D-xylose absorption test is deteriorated in 10–33% of the cases. Iron 
deficiency anemia and megaloblastic anemia can also help to diagnose in suspicious cases [87].
Genetic testing also can be used when needed for a proper diagnosis. The absence of HLA-DQ2 
and HLA-DQ8 alleles, mostly, gives the idea that the individual is unlikely to have DH. But 
the positivity of these alleles does not always mean that the patient has DH, because these 
alleles can be positive in normal population frequently [74].
Antiga and Caproni proposed a diagnostic algorithm in DH. According to this algorithm, in 
case of typical DIF findings and anti-tTG positivity, the diagnosis is certain. In a case with 
Figure 2. Granular IgA deposits at the tips of the dermal papillae.
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typical DIF findings but anti-tTG negativity, HLA testing is suggested. If HLA-DQ2 and 
HLA-DQ8 are negative, DH is excluded. If the alleles are positive, other mentioned antibod-
ies can be checked and intestinal biopsy can be performed. In case of DIF negativity and anti-
tTG positivity, HLA testing is recommended. If negative, DH can be excluded, but if positive, 
a new biopsy for immunofluorescence is recommended. In individuals who are negative for 
both DIF and anti-tTG, DH can be excluded [1].
6. Differential diagnosis
DH should be differentiated from other bullous skin disorders (such as linear IgA bullous 
dermatitis and bullous pemphigoid), urticaria, atopic dermatitis, nummular dermatitis, 
contact dermatitis, and scabies. Linear IgA bullous dermatitis (LABD) has clinical features 
similar to DH. Larger bullae and “crown of jewels” appearance of the lesions are charac-
teristics of LABD. “Linear” versus “granular” deposition on direct immunofluorescence is 
the best way to differentiate these two entities. An oil preparation will help to distinguish 
scabies from DH. Histopathological examination will help to rule out the other derma-
toses. Table 2 summarizes the differential diagnostic features of DH, LABD, and bullous 
pemphigoid.
7. Treatment
Gluten-free diet (GFD) is a must in the treatment of DH [88]. With GFD, not only the skin 
lesions resolve but also the pathological findings in intestine improve [89]. The IgA deposits 
disappear slowly and several years may be necessary for complete resolution. Ingestion of glu-
ten leads to immediate deposition of IgA in the skin and polymorphic eruption arises thereaf-
ter [90]. It is tough to stick to GFD. Thus, consultation with a dietician may be necessary and 
DH LABD BP
Lesion appearance Excoriated papules, vesicles 
that coalesce
Small vesicles and/or large 
bullae
Tense bullae
Distribution Extensor and symmetrical Extensor and symmetrical Trunk, extremities
Histopathology Subepidermal bullae, 
neutrophils
Subepidermal bullae, 
neutrophils
Subepidermal bullae, 
sometimes eosinophils
Direct IF Granular IgA in dermal 
papillae
Linear IgA at basement 
membrane
Linear IgG and C3 at 
basement membrane
Indirect IF Mostly (−) Linear IgA at BMZ Linear IgG at BMZ
GIS involvement >90% Mostly (−) (−)
Response to dapsone Excellent Good Minimal
Table 2. Differential diagnostic features of DH (dermatitis herpetiformis), LABD (linear IgA bullous dermatitis), and BP 
(bullous pemphigoid).
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helpful. Cereals (wheat, barley, and rye) and products containing cereals are rich in gluten [23]. 
GFD also decreases the malabsorption associated with gluten intolerance. GFD is also thought 
to minimize the risk of lymphoma, which is believed to be caused by continuous antigenic 
stimulation [91]. On GFD, gastrointestinal symptoms respond first; later on, the skin lesions 
respond. In the absence of an additional pharmacological therapy, it may take several years for 
the cutaneous lesions to disappear [65].
There are few studies that showed cases of DH refractory to GFD. In 2016, Hervonen et al. reported 7 
cases out of 403 (1.7%) who were refractory to GFD [92]. In another study, this ratio was nearly 7% [88].
In terms of pharmacotherapy, sulfones like dapsone and sulfapyridine, are accepted as golden 
standard. These drugs suppress the cutaneous disease immediately [93, 94]. Dapsone is an anti-
inflammatory and antibacterial drug which, downregulates neutrophil chemotaxis. As a result, 
tissue damage, triggered by neutrophils and eosinophils, is inhibited [95, 96]. Skin manifesta-
tions are relieved in a few days after dapsone initiation [97]. Usually 25–200 mg/day of dapsone 
is necessary to control the disease. It has been shown that dapsone alone does not improve 
the gastrointestinal disease. Therefore, combination of dapsone and GFD is considered as the 
mainstay of the treatment of DH. Some authors claim that upon strict GFD the dosage of dap-
sone can be lowered in time and even can be discontinued and restarted in times of flares [98].
The possible side effects of dapsone are well known. Some of the known side effects are the 
hematological ones such as methemoglobinemia [99]. Methemoglobinemia causes insufficient 
oxygen to the tissues and manifests by cyanosis, grayish-blue color, weakness, nausea, tachycar-
dia, and abdominal pain [54]. Close follow-up is necessary to rule out this side effect, especially at 
the beginning of the therapy. To decrease the possibility of methemoglobinemia, cimetidine and/
or vitamin E supplement can be prescribed [50]. Patients with glucose-6-phosphate dehydroge-
nase (G6PD) are more likely to develop hemolysis [100]. The dosage of dapsone must be lowered 
in these patients. Agranulocytosis is a rare but serious complication and is almost always seen 
at the beginning of the therapy [101]. Systemic drug hypersensitivity syndrome is another side 
effect of dapsone treatment, which must also be kept in mind [102]. The sulfone syndrome is seen 
in the first 2 months of the treatment. Exfoliative dermatitis, fever, lymphadenopathy, hepatitis, 
vomiting, and hemolysis are independent from the dosage [103, 104]. Table 3 summarizes the 
possible side effects of dapsone.
Sulfapyridine, which is the metabolite of both sulfasalazine and sulfamethoxypyridazine, is 
another therapeutic option in the treatment of DH. The mechanism of action is similar to that 
of dapsone [105].
Systemic steroids are usually reported to be useless in the treatment of DH [92]. In some 
instances, potent topical steroids can be used to relieve pruritus [106]. Topical steroids must 
be used during the acute stage together with the above-mentioned systemic agents.
Tetracycline and nicotinamide combination, colchicine, heparin, and cyclosporine are 
reported to be effective in the treatment of DH. But there are mostly limited case reports about 
these treatment options and they need further, large studies [107–109]. Sacchidanand, in 2003, 
reported good results in DH patients with dexamethasone-cyclophosphamide pulse therapy 
[110]. Topical dapsone, mycophenolate, and rituximab have also been used for the treatment 
of DH with variable results [111, 112].
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DH has a chronic nature with remissions and flares. That is why close consultation, long-
term GFD, and pharmacological treatment are necessary. In the course of the disease, 
regular screening for other autoimmune diseases and neoplastic conditions is generally rec-
ommended. Blood samples should be taken, at regular intervals, to monitor the possible side 
effects of the drugs. Anti-tTG and anti-eTG IgA levels can be used to evaluate the adherence 
of the patients to GFD.
Spontaneous remissions that last months or years are rarely reported. A spontaneous 
remission is mentioned when there are no lesions for at least 6 months without adherence 
to GFD [42].
Adverse effects of dapsone
Blood abnormality Hemolytic anemia
Methemoglobinemia
Agranulocytosis
Leukopenia
Gastrointestinal side effects Nausea
Hepatitis
Cholestasis
Hypoalbuminemia
Neurological side effects Headache
Peripheral neuropathy
Dizziness
Insomnia
Psychosis
Cutaneous reactions Maculopapular eruption
Urticarial reaction
Fixed drug eruption
Erythrodermia
Stevens-Johnson syndrome
Phototoxicity
Drug-induced lupus erythematosus
Dapsone hypersensitivity Hepatitis
Fatigue
Anorexia
Lymphadenopathy
Table 3. The side effects of dapsone.
Dermatitis Herpetiformis
http://dx.doi.org/10.5772/intechopen.71938
109
8. Childhood dermatitis herpetiformis
DH, in childhood, resembles the disease of the adulthood with some exceptional features. DH 
is most commonly seen between the ages of 2 and 7. Girls and boys are equally affected [113]. 
DH in childhood has an insidious course. It has a long period of pruritus, which is lesion free. 
The lesions are usually scattered in an asymmetric manner in contrast to adulthood form, 
which tends to coalesce [114]. Facial lesions are more common in childhood. Palmar linear 
petechiae and bullae are mostly seen in the childhood form. Chronic urticarial lesions, chronic 
dermatitis, and hemorrhagic bullae can accompany the classical lesions [48]. Aforementioned 
enamel defects, oral erosions, and chronic diarrhea can also be seen in the affected children 
[52, 53, 115].
Interestingly, children with DH can respond to topical steroid treatment initially. This 
response, at the beginning, diminishes in time [116]. Dapsone is the golden standard in terms 
of treatment. About 2 mg/kg/day is generally enough to control the disease. The response 
starts in 72 hours. After satisfactory response, the dosage can be lowered. The second choice 
is sulfapyridine at a dose of 35–70 mg/kg/day [96].
9. Conclusion
Dermatitis herpetiformis, when undiagnosed, is a distracting disease for the patient with its 
chronic nature and the itching. In case of a polymorphic eruption and pruritus, DH must come 
to mind. After proper history taking, physical examination, and laboratory investigations, its 
diagnosis is, mostly, easy. GFD and dapsone ensure an untroubled life for the patient. But we 
should, always, be aware of the possible side effects of the therapy.
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